Glaxosmithkline Share News (GSK)

AGM, EGM Calendar - Week Ahead

GSK expected to can capital return plan amid stagnant growth

GlaxoSmithKline may throw out a plan to return £4bn to shareholders amid an overhaul of the drugmaker and a new chairman, analysts have said. Goldman Sachs and Berenberg Bank believe GSK could instead use cash flowing from its asset swap deal with Novartis to support its dividend. Last year GSK sai

LONDON MIDDAY BRIEFING: Lloyds Banking Group Recovery Accelerates

Doubts grow over GlaxoSmithKline's $6 bln capital return plan

* Money may be used to shore up dividend -analysts * Cash return was planned after Novartis asset swap deal * GSK to showcase reshaped business at May 6 investor day By Ben Hirschler LONDON, May 1 (Reuters) - GlaxoSmithKline may ditch a plan to return 4 billion pounds ($6.

TOP NEWS: UK Manufacturing Growth Slows But Consumer Credit Expands

London open: Lloyds beats forecasts but markets fall ahead of long weekend

London stocks fell on Friday despite a better-than-expected first quarter from Lloyds Banking Group as investors were treading carefully in the absence of trading across Europe. The FTSE 100 was down 0.51% at 6,924.94 early on, with most equity markets on the continent closed for May Day. Analyst C

BROKER RATINGS SUMMARY: Berenberg Cuts Barclays To Sell From Hold

Glaxo and Theravance win FDA approval for Breo asthma treatment

Glaxosmithkline (GSK) has said its Breo once-daily treatment for adult asthma has been approved by the US Food and Drug Administration (FDA). Breo, developed with US pharmaceutical group Theravance, is a "fixed-dose combination of the inhaled corticosteroid (ICS) fluticasone furoate (FF) and the lon

LONDON MORNING BRIEFING: Lloyds Banking Results Please Market

LONDON MARKET COMMENT: Stocks Seen Lower; Lloyds Pretax Profit Falls

GlaxoSmithKline Says US FDA Approves Breo Ellipta For Asthma In Adults

AGM, EGM Calendar - Week Ahead

Earnings, Trading Statements Calendar - Week Ahead

UPDATE 1-Nexium, Advair led Medicare drug spending in 2013 -officials

(New throughout, adds more prescribing data and details of neurology drug price rise) By Sharon Begley NEW YORK, April 30 (Reuters) - Four brand-name medications accounted for almost one-tenth of the $103 billion in prescriptions filled by older or disabled Americans under Medicare's

Nexium, Advair led Medicare drug spending in 2013 - officials

By Sharon Begley NEW YORK, April 30 (Reuters) - Four brand-named drugs prescribed to older or disabled Americans covered by Medicare's drug benefit accounted for almost one-tenth of the $103 billion in prescriptions filled under the plan in 2013, U.S. officials reported on Thursday. T